Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

NCT04731298 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor Decision related to Business Priorities, Assessment of Development Options

Conditions

Interventions

Sponsor

Swedish Orphan Biovitrum

Collaborators